Evidence map›Paper›PMID 39869500›Full record

ArticleThe Biochemical journal2025

Characterisation of RNA guanine-7 methyltransferase (RNMT) using a small molecule approach.

Lesley-Anne Pearson, Alain-Pierre Petit, Cesar Mendoza Martinez, Fiona Bellany, De Lin, Sarah Niven, Rachel Swift, Thomas Eadsforth, Paul Fyfe, Marilyn Paul and 4 more

Erratum issuedAbstract read
In one paragraph

Article in The Biochemical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Lesley-Anne Pearson *Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Alain-Pierre Petit *Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Cesar Mendoza MartinezDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Fiona BellanyDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
De LinDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Sarah NivenDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Rachel SwiftDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Thomas EadsforthDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Paul FyfeDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Marilyn PaulDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Vincent PostisDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Xiao HuDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.
Victoria H CowlingSchool of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, U.K.ORCID 0000-0001-7638-4870
David W GrayDrug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, U.K.ORCID 0000-0001-9512-3828

Funding

Medical Research Council MC_PC_19034Wellcome TrustWellcome Trust 094090Wellcome Trust 203134/Z/16/Z
6 · The paper itself

Abstract

The maturation of the RNA cap involving guanosine N-7 methylation, catalyzsed by the HsRNMT (RNA guanine-7 methyltransferase (HsRNMT)-RAM (RNA guanine-N7 methyltransferase activating subunit (RAM) complex, is currently under investigation as a novel strategy to combat PIK3CA -mutant breast cancer. However, the development of effective drugs is hindered by a limited understanding of the enzyme's mechanism and a lack of small molecule inhibitors. Following the elucidation of the HsRNMT-RAM molecular mechanism, we report the biophysical characterizsation of two small molecule hits. Biophysics, biochemistry and structural biology confirm that both compounds bind competitively with cap and bind effectively to HsRNMT-RAM in the presence of the co-product SAH, with a binding affinity (KD) of approximately 1 μM. This stabilisation of the enzyme--product complex results in uncompetitive inhibition. Finally, we describe the properties of the cap pocket and provided suggestions for further development of the tool compounds.

Indexed as

Enzyme InhibitorsMethyltransferasesRNA CapsSmall Molecule LibrariesHumansProtein BindingEnzyme InhibitorsMethyltransferasesmRNA (guanine(N7))-methyltransferaseRNA CapsSmall Molecule Librariesbreast cancermethyl transferaseRNMTSinefungin

Identifiers

PMID39869500
PMCPMC12133303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.